Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Pompano Beach, FL, Feb. 16, 2018 -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, announced today that it has completed its application to uplist on OTCQX, a higher tier Over The Counter (OTC) market overseen by OTCMarkets, Inc.
OTCQX is a segment of the OTC marketplace reserved for publicly traded companies that have: (a) attained specific quantitative and qualitative financial standards; (b) passed management reviews; (c) issued timely information to the public; (d) remained current on required disclosures, and (e) consistently shared pertinent updates with investors. OTCQX companies are more widely quoted across the electronic and retail brokerage markets.
Henry Van Vurst, CEO of BioStem Technologies, stated, "We’ve been aggressively preparing for this uplist for months now, meeting all financial reporting obligations and completing the submission of all application documents required by OTCMarkets, Inc. We expect the uplist to add value for our shareholders by enabling our stock to be quoted and traded by a much wider range of brokerages, particularly retail brokers.”
The stocks of approximately 10,000 companies are traded daily in the multi-tiered OTC Markets, but only companies in the top tier qualify to trade on the OTCQX. Those companies are characterized by operational excellence and consistent reporting diligence. “BSEM is certainly qualified for that top tier, and we expect our application to be quickly approved,” added Mr. Van Vurst.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. Phone: 954-380-8342 Website: http://www.biostemtech.com Email: [email protected] Twitter: @Biostemtech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst [email protected] (954) 380-8342
